Market Intelligence, Clinical Progress, and High-Purity Reagents for Wnt Signaling and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TCF4/TCF7L2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TCF7L2 (TCF4) Recombinant / Mutant Protein: Full-length, HMG DNA-binding domain, β-catenin binding domain. High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. Theoretical MW confirmed by mass spectrometry. | View TCF7L2 Products |
| Gene Delivery | TCF7L2 Promise-ORF / Lentivirus: Full-length ORF with native isoform configuration for stable reporter cell lines (TopFlash/FOPFlash). Titer >10⁸ TU/ml. | View TCF7L2 Products |
| Benchmark Ab | Anti-TCF7L2 (TCF4) Recombinant Antibody: ChIP/IP-grade positive control for western blot, immunoprecipitation, and ChIP assays. | View TCF7L2 Products |
| Validator | TCF7L2 siRNA Set: Sequence-specific, validated for knockdown verification in reporter assays and ChIP. No cross-reactivity with TCF7/LEF1. | View TCF7L2 Products |
| Related Target A | CTNNB1 (β-catenin): Direct PPI partner; essential for co-precipitation and disruption assays. | View CTNNB1 Products |
| Related Target B | APC: Negative regulator of Wnt signaling upstream of TCF4; mutation status drives constitutive activation. | View APC Products |
| Related Target C | LEF1: TCF/LEF paralog for critical selectivity counter-screening to avoid pan-Wnt toxicity. | View LEF1 Products |
| Related Target D | LRP6: Upstream Wnt co-receptor; combination screening for pathway modulation. | View LRP6 Products |
| Related Target E | AXIN1: Destruction complex scaffold; mutant forms available for signaling studies. | View AXIN1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (β-catenin binding) screening | High-purity TCF7L2 HMG domain & full-length protein (>95% purity, endotoxin <1EU/μg) for SPR and AlphaScreen/TR-FRET. |
| DNA-binding validation (EMSA/FP) | Sequence-verified HMG domain with theoretical MW confirmed by mass spec; suitable for TCF/LEF motif binding studies. |
| Isoform, Variant & Mutant Control | Sequence-verified specific splice variants, T2D-associated risk alleles, and engineered β-catenin binding-deficient mutants (interface K-to-A) for rigorous specificity validation. |
| TCF/LEF family selectivity (off-target avoidance) | Human TCF7L2, TCF7, TCF7L1, and LEF1 ortholog proteins available with >95% purity; validated TCF7L2-specific siRNA (no cross-reactivity). |
| Cellular reporter assay standardization | HEK293 expressed lentivirus particles for stable TopFlash/FOPFlash reporter line generation; preserves native folding. |
| False Positive Control | Validated siRNA and rescue ORF lentivirus included for target-specificity checks; clinical benchmark antibodies for assay normalization. |
Global Clinical Landscape & Future Outlook
The therapeutic targeting of TCF7L2 (TCF4) represents a paradigm shift from upstream Wnt pathway modulation (Frizzled, Porcupine inhibitors) to direct nuclear transcription factor blockade. As a critical downstream effector of the Wnt/β-catenin pathway, TCF4 is highly implicated in colorectal cancer (APC mutation-driven) and Type 2 Diabetes (robust GWAS risk variant rs7903146). Historically considered "undruggable" due to its intracellular localization and lack of enzymatic pocket, recent advances in stapled peptides, small molecule PPI inhibitors, and PROTAC technology have enabled specific disruption of the TCF7L2/β-catenin interaction. Current R&D bifurcates between metabolic disease and oncology (colorectal, pancreatic cancers). The next wave emphasizes dominant-negative mutant forms, allele-specific inhibitors, and combination therapies with immune checkpoint inhibitors to overcome toxicity and resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | PRI-724 (Prism BioLab), ICG-001 analogs; Biotech Startups, Academic Spin-offs | Colorectal Cancer, Hepatic Fibrosis, Solid Tumors | Purified TCF7L2/β-catenin domains for displacement assays (AlphaScreen/TR-FRET). |
| Peptide / Peptidomimetic | Academic Consortia (Stapled Peptides) | Type 2 Diabetes, Solid Tumors | Cell permeability & nuclear localization assays (need lentiviral reporter lines). |
| PROTAC / Degrader | Emerging Biotech (Undisclosed) | Drug-resistant Wnt-driven Cancers | High-quality TCF7L2 substrate for ternary complex formation; ubiquitination assays. |
| siRNA / ASO / Gene Therapy | RNA Therapeutics Cos., Preclinical (Metabolic Focus) | T2DM, NAFLD, Oncology | Knockdown validation (need sequence-verified siRNA and ChIP-grade antibodies). |
Live TCF4/TCF7L2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: